Methylxanthine adenosine receptor antagonist

Plain-language summaryIntrigue 65 / 100

Caffeine is the world’s most widely consumed psychoactive substance. It blocks adenosine receptors that normally promote sleep, producing alertness and reduced fatigue. The half-life of about 5 hours means that an afternoon coffee can disrupt nighttime sleep. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundGeneric nutrient

30/100

Thoroughly understood adenosine antagonist with no meaningful frontier research value left to extract

Look, caffeine. We don’t really need to introduce it. 1,3,7-trimethylxanthine is in every cup of coffee on the planet, and the research community has been publishing on adenosine receptor antagonism since before the compound was even fully structurally characterized in the 19th century. The mechanism isn’t contested. The compound isn’t mysterious. And thats precisely why it scores where it does.

The adenosine receptor story is genuinely elegant biology, and we’ll give it that. A2A antagonism in the basal ganglia drives wakefulness and motor effects; A1 antagonism in the cortex modulates neurotransmitter release; at supratherapeutic concentrations, PDE inhibition adds a wrinkle to the cAMP picture. We know all of this. A PubMed query for caffeine returns over 20,000 entries. The receptor pharmacology was worked out decades ago. If you’re trying to probe adenosine receptor biology cleanly, you’d reach for something like ZM 241385 or SCH 58261 as selective tool compounds. Caffeine hits A1, A2A, A2B, and A3 with varying affinity, and that nonselective profile creates confounds rather than clarity at the bench.

The evidence quality is high, and we’re scoring that honestly. Hundreds of replicated human trials, Cochrane-grade meta-analyses on cognitive performance, endurance, and headache prophylaxis, and a well-characterized PK profile including the CYP1A2 polymorphism story. Translational signal is strong in the sense that the compound clearly does what people think it does in actual humans. But the problem is exactly that: it’s been investigated so thoroughly that additional research contributes almost nothing new to the scientific picture. The confidence intervals around cognitive effects are already tight. The dose-response curve is mapped. Tolerance kinetics are described in literature going back decades.

What’s the bench case for running experiments with caffeine in 2025? The straightforward adenosine-antagonism questions are answered. Any novel angle, say caffeine in the context of neuroinflammation or in synergy with other neuromodulators, would typically position caffeine as a reference arm or positive control rather than the primary subject. That’s bench value in the context of controlling for a known variable, not in generating new biology. We score those things differently.

Honestly, caffeine sits in the library because it’s relevant to stack interactions and sourcing context, not because it’s a frontier research target. If adenosine receptor biology is what you’re after, newer and more selective tool compounds give you cleaner signal. Caffeine is foundational reference knowledge. The score reflects that: genuinely well-understood, genuinely effective in humans, and genuinely not what a serious investigator would center a research program around right now.

Novelty: 8
Mechanism promise: 12
In-category differentiation: 10
Evidence quality: 72
Translational signal: 70
Research bench value: 22

Rationale Novelty, mechanism interest, and differentiation all score near floor because adenosine receptor pharmacology is solved and the compound is the textbook example of a mature, fully-characterized molecule; evidence and translational scores are genuinely high but reflect past research saturation rather than future opportunity. The common-OTC cap (35) does not bind since the raw weighted score lands at 30.

Methylxanthine adenosine receptor antagonist

The world’s most consumed psychoactive substance, an adenosine receptor antagonist with widespread cognitive and physical performance effects.

Abstract

Caffeine (1,3,7-trimethylxanthine; CAS 58-08-2; molecular formula C8H10N4O2; molecular weight 194.19) is the most widely consumed psychoactive substance in the world, present in coffee, tea, cocoa, and many caffeinated beverages and dietary supplements. Mechanism is non-selective adenosine receptor antagonism (A1, A2A, A2B, A3) at typical dietary doses, with secondary inhibition of phosphodiesterase and modulation of GABA-A receptors at supratherapeutic concentrations. The adenosine A2A receptor antagonism is the principal driver of cognitive and motor effects. Pharmacokinetics: plasma half-life 3 to 5 hours; CYP1A2 metabolism (variable by genotype); renal excretion of metabolites. Doses for performance applications are typically 100 to 400 mg; tolerance develops within 1 to 2 weeks of regular use.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-162Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Methylxanthine adenosine receptor antagonist

Caffeine

Abstract

Read the full monograph